Skip to main content
PMC home page
Journal of Psychiatry & Neuroscience : JPN logoLink to Journal of Psychiatry & Neuroscience : JPN
. 1996 Jan;21(1):36–48.

Eating disorder and obsessive-compulsive disorder: neurochemical and phenomenological commonalities.

J L Jarry 1, F J Vaccarino 1
PMCID: PMC1188732  PMID: 8580116

Abstract

This paper explores a possible connection between neurochemistry and cognitions in eating disorders (ED). Cognitions play an important role in ED. However, a possible neurochemical origin of these cognitions has not been explored. Obsessive-compulsive disorder (OCD) is known as a disorder of thinking. Extensive neurochemical research conducted on this disorder indicates a connection between serotonin (5-HT) dysregulation and cognitions in OCD. This study used research done on OCD as a template to interpret the available research findings in ED and their possible meaning in terms of neurochemical origin of cognitions in ED. This paper suggests that the neurochemical and behavioral expression of both ED and OCD occur on a continuum. At one end of the continuum, ED and OCD are expressed through constrained behaviors of an avoidant quality. This pole is also characterized by high levels of serotonin markers. At the other end, both disorders are characterized by disinhibited approach behavior. This end of the continuum is characterized by low levels of 5-HT markers. It is suggested that these levels of 5-HT generate cognitions that may in turn promote specific behaviors.

Full text

PDF
36

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altamura A. C., Montgomery S. A., Wernicke J. F. The evidence for 20mg a day of fluoxetine as the optimal dose in the treatment of depression. Br J Psychiatry Suppl. 1988 Sep;(3):109–112. [PubMed] [Google Scholar]
  2. Altemus M., Swedo S. E., Leonard H. L., Richter D., Rubinow D. R., Potter W. Z., Rapoport J. L. Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch Gen Psychiatry. 1994 Oct;51(10):794–803. doi: 10.1001/archpsyc.1994.03950100042004. [DOI] [PubMed] [Google Scholar]
  3. Ananth J., Pecknold J. C., van den Steen N., Engelsmann F. Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharmacol. 1981;5(3):257–262. doi: 10.1016/0364-7722(81)90077-1. [DOI] [PubMed] [Google Scholar]
  4. Baer L., Jenike M. A. Personality disorders in obsessive compulsive disorder. Psychiatr Clin North Am. 1992 Dec;15(4):803–812. [PubMed] [Google Scholar]
  5. Baer L., Jenike M. A., Ricciardi J. N., 2nd, Holland A. D., Seymour R. J., Minichiello W. E., Buttolph M. L. Standardized assessment of personality disorders in obsessive-compulsive disorder. Arch Gen Psychiatry. 1990 Sep;47(9):826–830. doi: 10.1001/archpsyc.1990.01810210034005. [DOI] [PubMed] [Google Scholar]
  6. Bastani B., Arora R. C., Meltzer H. Y. Serotonin uptake and imipramine binding in the blood platelets of obsessive-compulsive disorder patients. Biol Psychiatry. 1991 Jul 15;30(2):131–139. doi: 10.1016/0006-3223(91)90166-j. [DOI] [PubMed] [Google Scholar]
  7. Benkelfat C., Murphy D. L., Zohar J., Hill J. L., Grover G., Insel T. R. Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action. Arch Gen Psychiatry. 1989 Jan;46(1):23–28. doi: 10.1001/archpsyc.1989.01810010025004. [DOI] [PubMed] [Google Scholar]
  8. Beumont P. J., George G. C., Smart D. E. "Dieters" and "vomiters and purgers" in anorexia nervosa. Psychol Med. 1976 Nov;6(4):617–622. [PubMed] [Google Scholar]
  9. Black D. W., Kelly M., Myers C., Noyes R., Jr Tritiated imipramine binding in obsessive-compulsive volunteers and psychiatrically normal controls. Biol Psychiatry. 1990 Feb 1;27(3):319–327. doi: 10.1016/0006-3223(90)90006-n. [DOI] [PubMed] [Google Scholar]
  10. Black D. W., Noyes R., Jr, Pfohl B., Goldstein R. B., Blum N. Personality disorder in obsessive-compulsive volunteers, well comparison subjects, and their first-degree relatives. Am J Psychiatry. 1993 Aug;150(8):1226–1232. doi: 10.1176/ajp.150.8.1226. [DOI] [PubMed] [Google Scholar]
  11. Blier P., Chaput Y., de Montigny C. Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: an electrophysiological study in the rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1988 Mar;337(3):246–254. doi: 10.1007/BF00168834. [DOI] [PubMed] [Google Scholar]
  12. Blier P., De Montigny C. Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat. J Neurosci. 1983 Jun;3(6):1270–1278. doi: 10.1523/JNEUROSCI.03-06-01270.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Blier P., de Montigny C., Tardif D. Effects of the two antidepressant drugs mianserin and indalpine on the serotonergic system: single-cell studies in the rat. Psychopharmacology (Berl) 1984;84(2):242–249. doi: 10.1007/BF00427453. [DOI] [PubMed] [Google Scholar]
  14. Bond W. S., Crabbe S., Sanders M. C. Pharmacotherapy of eating disorders: a critical review. Drug Intell Clin Pharm. 1986 Sep;20(9):659–665. doi: 10.1177/106002808602000903. [DOI] [PubMed] [Google Scholar]
  15. Brewerton T. D., Murphy D. L., Jimerson D. C. Testmeal responses following m-chlorophenylpiperazine and L-tryptophan in bulimics and controls. Neuropsychopharmacology. 1994 Aug;11(1):63–71. doi: 10.1038/npp.1994.36. [DOI] [PubMed] [Google Scholar]
  16. Bulik C. M., Beidel D. C., Duchmann E., Weltzin T. E., Kaye W. H. Comparative psychopathology of women with bulimia nervosa and obsessive-compulsive disorder. Compr Psychiatry. 1992 Jul-Aug;33(4):262–268. doi: 10.1016/0010-440x(92)90051-q. [DOI] [PubMed] [Google Scholar]
  17. Chaput Y., de Montigny C., Blier P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1986 Aug;333(4):342–348. doi: 10.1007/BF00500007. [DOI] [PubMed] [Google Scholar]
  18. Charney D. S., Goodman W. K., Price L. H., Woods S. W., Rasmussen S. A., Heninger G. R. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry. 1988 Feb;45(2):177–185. doi: 10.1001/archpsyc.1988.01800260095012. [DOI] [PubMed] [Google Scholar]
  19. Charney D. S., Woods S. W., Krystal J. H., Heninger G. R. Serotonin function and human anxiety disorders. Ann N Y Acad Sci. 1990;600:558–573. doi: 10.1111/j.1749-6632.1990.tb16910.x. [DOI] [PubMed] [Google Scholar]
  20. Chouinard G., Goodman W., Greist J., Jenike M., Rasmussen S., White K., Hackett E., Gaffney M., Bick P. A. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull. 1990;26(3):279–284. [PubMed] [Google Scholar]
  21. Christenson G. A., Pyle R. L., Mitchell J. E. Estimated lifetime prevalence of trichotillomania in college students. J Clin Psychiatry. 1991 Oct;52(10):415–417. [PubMed] [Google Scholar]
  22. Cooper J. The Leyton obsessional inventory. Psychol Med. 1970 Nov;1(1):48–64. doi: 10.1017/s0033291700040010. [DOI] [PubMed] [Google Scholar]
  23. Crown S., Crisp A. H. A short clinical diagnostic self-rating scale for psychoneurotic patients. The Middlesex Hospital Questionnaire (M.H.Q.). Br J Psychiatry. 1966 Sep;112(490):917–923. doi: 10.1192/bjp.112.490.917. [DOI] [PubMed] [Google Scholar]
  24. Eison A. S., Eison M. S. Serotonergic mechanisms in anxiety. Prog Neuropsychopharmacol Biol Psychiatry. 1994 Jan;18(1):47–62. doi: 10.1016/0278-5846(94)90023-x. [DOI] [PubMed] [Google Scholar]
  25. Fava M., Copeland P. M., Schweiger U., Herzog D. B. Neurochemical abnormalities of anorexia nervosa and bulimia nervosa. Am J Psychiatry. 1989 Aug;146(8):963–971. doi: 10.1176/ajp.146.8.963. [DOI] [PubMed] [Google Scholar]
  26. Garner D. M., Garfinkel P. E. The Eating Attitudes Test: an index of the symptoms of anorexia nervosa. Psychol Med. 1979 May;9(2):273–279. doi: 10.1017/s0033291700030762. [DOI] [PubMed] [Google Scholar]
  27. Gerner R. H., Cohen D. J., Fairbanks L., Anderson G. M., Young J. G., Scheinin M., Linnoila M., Shaywitz B. A., Hare T. A. CSF neurochemistry of women with anorexia nervosa and normal women. Am J Psychiatry. 1984 Nov;141(11):1441–1444. doi: 10.1176/ajp.141.11.1441. [DOI] [PubMed] [Google Scholar]
  28. Goldbloom D. S., Garfinkel P. E. The serotonin hypothesis of bulimia nervosa: theory and evidence. Can J Psychiatry. 1990 Dec;35(9):741–744. doi: 10.1177/070674379003500904. [DOI] [PubMed] [Google Scholar]
  29. Goldbloom D. S., Hicks L. K., Garfinkel P. E. Platelet serotonin uptake in bulimia nervosa. Biol Psychiatry. 1990 Oct 1;28(7):644–647. doi: 10.1016/0006-3223(90)90404-p. [DOI] [PubMed] [Google Scholar]
  30. Goodman W. K., Price L. H., Delgado P. L., Palumbo J., Krystal J. H., Nagy L. M., Rasmussen S. A., Heninger G. R., Charney D. S. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry. 1990 Jun;47(6):577–585. doi: 10.1001/archpsyc.1990.01810180077011. [DOI] [PubMed] [Google Scholar]
  31. Greist J. H., Jefferson J. W., Kobak K. A., Katzelnick D. J., Serlin R. C. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry. 1995 Jan;52(1):53–60. doi: 10.1001/archpsyc.1995.03950130053006. [DOI] [PubMed] [Google Scholar]
  32. Gwirtsman H. E., Guze B. H., Yager J., Gainsley B. Fluoxetine treatment of anorexia nervosa: an open clinical trial. J Clin Psychiatry. 1990 Sep;51(9):378–382. [PubMed] [Google Scholar]
  33. Hallman J., Sakurai E., Oreland L. Blood platelet monoamine oxidase activity, serotonin uptake and release rates in anorexia and bulimia patients and in healthy controls. Acta Psychiatr Scand. 1990 Jan;81(1):73–77. doi: 10.1111/j.1600-0447.1990.tb06452.x. [DOI] [PubMed] [Google Scholar]
  34. Halmi K. A., Eckert E., LaDu T. J., Cohen J. Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry. 1986 Feb;43(2):177–181. doi: 10.1001/archpsyc.1986.01800020087011. [DOI] [PubMed] [Google Scholar]
  35. Hassanyeh F., Marshall E. F. Measures of serotonin metabolism in anorexia nervosa. Acta Psychiatr Scand. 1991 Dec;84(6):561–563. doi: 10.1111/j.1600-0447.1991.tb03195.x. [DOI] [PubMed] [Google Scholar]
  36. Hollander E., DeCaria C. M., Nitescu A., Gully R., Suckow R. F., Cooper T. B., Gorman J. M., Klein D. F., Liebowitz M. R. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry. 1992 Jan;49(1):21–28. doi: 10.1001/archpsyc.1992.01820010021003. [DOI] [PubMed] [Google Scholar]
  37. Hollander E., DeCaria C. M., Schneier F. R., Schneier H. A., Liebowitz M. R., Klein D. F. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. J Clin Psychiatry. 1990 Mar;51(3):119–123. [PubMed] [Google Scholar]
  38. Hollander E., DeCaria C., Gully R., Nitescu A., Suckow R. F., Gorman J. M., Klein D. F., Liebowitz M. R. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Res. 1991 Jan;36(1):1–17. doi: 10.1016/0165-1781(91)90113-4. [DOI] [PubMed] [Google Scholar]
  39. Hoyer D., Clarke D. E., Fozard J. R., Hartig P. R., Martin G. R., Mylecharane E. J., Saxena P. R., Humphrey P. P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev. 1994 Jun;46(2):157–203. [PubMed] [Google Scholar]
  40. Hsu L. K., Kaye W., Weltzin T. Are the eating disorders related to obsessive compulsive disorder? Int J Eat Disord. 1993 Nov;14(3):305–318. doi: 10.1002/1098-108x(199311)14:3<305::aid-eat2260140309>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  41. Hudson J. I., Pope H. G., Jr, Jonas J. M., Yurgelun-Todd D. Phenomenologic relationship of eating disorders to major affective disorder. Psychiatry Res. 1983 Aug;9(4):345–354. doi: 10.1016/0165-1781(83)90008-2. [DOI] [PubMed] [Google Scholar]
  42. Hudson J. I., Pope H. G., Jr, Yurgelun-Todd D., Jonas J. M., Frankenburg F. R. A controlled study of lifetime prevalence of affective and other psychiatric disorders in bulimic outpatients. Am J Psychiatry. 1987 Oct;144(10):1283–1287. doi: 10.1176/ajp.144.10.1283. [DOI] [PubMed] [Google Scholar]
  43. Insel T. R., Mueller E. A., Alterman I., Linnoila M., Murphy D. L. Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry. 1985 Nov;20(11):1174–1188. doi: 10.1016/0006-3223(85)90176-3. [DOI] [PubMed] [Google Scholar]
  44. Insel T. R., Murphy D. L., Cohen R. M., Alterman I., Kilts C., Linnoila M. Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry. 1983 Jun;40(6):605–612. doi: 10.1001/archpsyc.1983.04390010015002. [DOI] [PubMed] [Google Scholar]
  45. Joffe R. T., Swinson R. P. Eating Attitudes Test scores of patients with obsessive-compulsive disorder. Am J Psychiatry. 1987 Nov;144(11):1510–1511. doi: 10.1176/ajp.144.11.1510b. [DOI] [PubMed] [Google Scholar]
  46. Joffe R. T., Swinson R. P., Regan J. J. Personality features of obsessive-compulsive disorder. Am J Psychiatry. 1988 Sep;145(9):1127–1129. doi: 10.1176/ajp.145.9.1127. [DOI] [PubMed] [Google Scholar]
  47. Kahn R. S., Kalus O., Wetzler S., Cahn W., Asnis G. M., van Praag H. M. Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects. Psychiatry Res. 1990 Aug;33(2):189–198. doi: 10.1016/0165-1781(90)90073-e. [DOI] [PubMed] [Google Scholar]
  48. Karno M., Golding J. M., Sorenson S. B., Burnam M. A. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry. 1988 Dec;45(12):1094–1099. doi: 10.1001/archpsyc.1988.01800360042006. [DOI] [PubMed] [Google Scholar]
  49. Katz R. J., DeVeaugh-Geiss J. The antiobsessional effects of clomipramine do not require concomitant affective disorder. Psychiatry Res. 1990 Feb;31(2):121–129. doi: 10.1016/0165-1781(90)90115-l. [DOI] [PubMed] [Google Scholar]
  50. Kaye N. S., Dancu C. Paroxetine and obsessive-compulsive disorder. Am J Psychiatry. 1994 Oct;151(10):1523–1523. doi: 10.1176/ajp.151.10.1523b. [DOI] [PubMed] [Google Scholar]
  51. Kaye W. H., Ballenger J. C., Lydiard R. B., Stuart G. W., Laraia M. T., O'Neil P., Fossey M. D., Stevens V., Lesser S., Hsu G. CSF monoamine levels in normal-weight bulimia: evidence for abnormal noradrenergic activity. Am J Psychiatry. 1990 Feb;147(2):225–229. doi: 10.1176/ajp.147.2.225. [DOI] [PubMed] [Google Scholar]
  52. Kaye W. H., Ebert M. H., Gwirtsman H. E., Weiss S. R. Differences in brain serotonergic metabolism between nonbulimic and bulimic patients with anorexia nervosa. Am J Psychiatry. 1984 Dec;141(12):1598–1601. doi: 10.1176/ajp.141.12.1598. [DOI] [PubMed] [Google Scholar]
  53. Kaye W. H., Ebert M. H., Raleigh M., Lake R. Abnormalities in CNS monoamine metabolism in anorexia nervosa. Arch Gen Psychiatry. 1984 Apr;41(4):350–355. doi: 10.1001/archpsyc.1984.01790150040007. [DOI] [PubMed] [Google Scholar]
  54. Kaye W. H., Gwirtsman H. E., George D. T., Ebert M. H. Altered serotonin activity in anorexia nervosa after long-term weight restoration. Does elevated cerebrospinal fluid 5-hydroxyindoleacetic acid level correlate with rigid and obsessive behavior? Arch Gen Psychiatry. 1991 Jun;48(6):556–562. doi: 10.1001/archpsyc.1991.01810300068010. [DOI] [PubMed] [Google Scholar]
  55. Kaye W. H., Gwirtsman H. E., George D. T., Jimerson D. C., Ebert M. H. CSF 5-HIAA concentrations in anorexia nervosa: reduced values in underweight subjects normalize after weight gain. Biol Psychiatry. 1988 Jan 1;23(1):102–105. doi: 10.1016/0006-3223(88)90113-8. [DOI] [PubMed] [Google Scholar]
  56. Kaye W. H., Weltzin T. E., Hsu L. K., Bulik C. M. An open trial of fluoxetine in patients with anorexia nervosa. J Clin Psychiatry. 1991 Nov;52(11):464–471. [PubMed] [Google Scholar]
  57. Kim S. W., Dysken M. W., Pandey G. N., Davis J. M. Platelet 3H-imipramine binding sites in obsessive-compulsive behavior. Biol Psychiatry. 1991 Sep 1;30(5):467–474. doi: 10.1016/0006-3223(91)90308-9. [DOI] [PubMed] [Google Scholar]
  58. Kim S. W., Dysken M. W., Pandey G. N., Davis J. M. Platelet 3H-imipramine binding sites in obsessive-compulsive behavior. Biol Psychiatry. 1991 Sep 1;30(5):467–474. doi: 10.1016/0006-3223(91)90308-9. [DOI] [PubMed] [Google Scholar]
  59. Kruesi M. J., Rapoport J. L., Hamburger S., Hibbs E., Potter W. Z., Lenane M., Brown G. L. Cerebrospinal fluid monoamine metabolites, aggression, and impulsivity in disruptive behavior disorders of children and adolescents. Arch Gen Psychiatry. 1990 May;47(5):419–426. doi: 10.1001/archpsyc.1990.01810170019003. [DOI] [PubMed] [Google Scholar]
  60. Laessle R. G., Kittl S., Fichter M. M., Wittchen H. U., Pirke K. M. Major affective disorder in anorexia nervosa and bulimia. A descriptive diagnostic study. Br J Psychiatry. 1987 Dec;151:785–789. doi: 10.1192/bjp.151.6.785. [DOI] [PubMed] [Google Scholar]
  61. Leckman J. F., Goodman W. K., Riddle M. A., Hardin M. T., Anderson G. M. Low CSF 5HIAA and obsessions of violence: report of two cases. Psychiatry Res. 1990 Jul;33(1):95–99. doi: 10.1016/0165-1781(90)90152-u. [DOI] [PubMed] [Google Scholar]
  62. Lenane M. C., Swedo S. E., Leonard H., Pauls D. L., Sceery W., Rapoport J. L. Psychiatric disorders in first degree relatives of children and adolescents with obsessive compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1990 May;29(3):407–412. doi: 10.1097/00004583-199005000-00012. [DOI] [PubMed] [Google Scholar]
  63. Leonard H. L., Swedo S. E., Lenane M. C., Rettew D. C., Cheslow D. L., Hamburger S. D., Rapoport J. L. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry. 1991 Oct;48(10):922–927. doi: 10.1001/archpsyc.1991.01810340054007. [DOI] [PubMed] [Google Scholar]
  64. Linnoila M., Virkkunen M., Scheinin M., Nuutila A., Rimon R., Goodwin F. K. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci. 1983 Dec 26;33(26):2609–2614. doi: 10.1016/0024-3205(83)90344-2. [DOI] [PubMed] [Google Scholar]
  65. Marazziti D., Hollander E., Lensi P., Ravagli S., Cassano G. B. Peripheral markers of serotonin and dopamine function in obsessive-compulsive disorder. Psychiatry Res. 1992 Apr;42(1):41–51. doi: 10.1016/0165-1781(92)90037-4. [DOI] [PubMed] [Google Scholar]
  66. Marazziti D., Macchi E., Rotondo A., Placidi G. F., Cassano G. B. Involvement of serotonin system in bulimia. Life Sci. 1988;43(25):2123–2126. doi: 10.1016/0024-3205(88)90362-1. [DOI] [PubMed] [Google Scholar]
  67. Mavissakalian M., Hamann M. S., Jones B. Correlates of DSM-III personality disorder in obsessive-compulsive disorder. Compr Psychiatry. 1990 Nov-Dec;31(6):481–489. doi: 10.1016/0010-440x(90)90062-w. [DOI] [PubMed] [Google Scholar]
  68. Mueller E. A., Murphy D. L., Sunderland T. Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans. Psychopharmacology (Berl) 1986;89(3):388–391. doi: 10.1007/BF00174380. [DOI] [PubMed] [Google Scholar]
  69. Mueller E. A., Murphy D. L., Sunderland T., Jones J. A new postsynaptic serotonin receptor agonist suitable for studies in humans. Psychopharmacol Bull. 1985;21(3):701–704. [PubMed] [Google Scholar]
  70. Mueller E. A., Murphy D. L., Sunderland T. Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans. J Clin Endocrinol Metab. 1985 Dec;61(6):1179–1184. doi: 10.1210/jcem-61-6-1179. [DOI] [PubMed] [Google Scholar]
  71. Murphy D. L., Zohar J., Benkelfat C., Pato M. T., Pigott T. A., Insel T. R. Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder. Br J Psychiatry Suppl. 1989 Dec;(8):15–24. [PubMed] [Google Scholar]
  72. Nemeroff C. B. The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor. Pharmacotherapy. 1994 Mar-Apr;14(2):127–138. [PubMed] [Google Scholar]
  73. Pato M. T., Zohar-Kadouch R., Zohar J., Murphy D. L. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry. 1988 Dec;145(12):1521–1525. doi: 10.1176/ajp.145.12.1521. [DOI] [PubMed] [Google Scholar]
  74. Pigott T. A., Altemus M., Rubenstein C. S., Hill J. L., Bihari K., L'Heureux F., Bernstein S., Murphy D. L. Symptoms of eating disorders in patients with obsessive-compulsive disorder. Am J Psychiatry. 1991 Nov;148(11):1552–1557. doi: 10.1176/ajp.148.11.1552. [DOI] [PubMed] [Google Scholar]
  75. Pigott T. A., Zohar J., Hill J. L., Bernstein S. E., Grover G. N., Zohar-Kadouch R. C., Murphy D. L. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991 Mar 1;29(5):418–426. doi: 10.1016/0006-3223(91)90264-m. [DOI] [PubMed] [Google Scholar]
  76. Rapoport J. L., Ryland D. H., Kriete M. Drug treatment of canine acral lick. An animal model of obsessive-compulsive disorder. Arch Gen Psychiatry. 1992 Jul;49(7):517–521. doi: 10.1001/archpsyc.1992.01820070011002. [DOI] [PubMed] [Google Scholar]
  77. Rasmussen S. A. Lithium and tryptophan augmentation in clomipramine-resistant obsessive-compulsive disorder. Am J Psychiatry. 1984 Oct;141(10):1283–1285. doi: 10.1176/ajp.141.10.1283. [DOI] [PubMed] [Google Scholar]
  78. Rasmussen S. A., Tsuang M. T. Clinical characteristics and family history in DSM-III obsessive-compulsive disorder. Am J Psychiatry. 1986 Mar;143(3):317–322. doi: 10.1176/ajp.143.3.317. [DOI] [PubMed] [Google Scholar]
  79. Rasmussen S. A., Tsuang M. T. The epidemiology of obsessive compulsive disorder. J Clin Psychiatry. 1984 Nov;45(11):450–457. [PubMed] [Google Scholar]
  80. Reynolds C. F., 3rd, Hoch C. C., Stack J., Campbell D. The nature and management of sleep/wake disturbance in Alzheimer's dementia. Psychopharmacol Bull. 1988;24(1):43–48. [PubMed] [Google Scholar]
  81. Robins L. N., Helzer J. E., Weissman M. M., Orvaschel H., Gruenberg E., Burke J. D., Jr, Regier D. A. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry. 1984 Oct;41(10):949–958. doi: 10.1001/archpsyc.1984.01790210031005. [DOI] [PubMed] [Google Scholar]
  82. Rothenberg A. Differential diagnosis of anorexia nervosa and depressive illness: a review of 11 studies. Compr Psychiatry. 1988 Jul-Aug;29(4):427–432. doi: 10.1016/0010-440x(88)90024-7. [DOI] [PubMed] [Google Scholar]
  83. Rothenberg A. Eating disorder as a modern obsessive-compulsive syndrome. Psychiatry. 1986 Feb;49(1):45–53. doi: 10.1080/00332747.1986.11024306. [DOI] [PubMed] [Google Scholar]
  84. Roy A., Adinoff B., Linnoila M. Acting out hostility in normal volunteers: negative correlation with levels of 5HIAA in cerebrospinal fluid. Psychiatry Res. 1988 May;24(2):187–194. doi: 10.1016/0165-1781(88)90061-3. [DOI] [PubMed] [Google Scholar]
  85. Solyom L., Freeman R. J., Miles J. E. A comparative psychometric study of anorexia nervosa and obsessive neurosis. Can J Psychiatry. 1982 Jun;27(4):282–286. doi: 10.1177/070674378202700404. [DOI] [PubMed] [Google Scholar]
  86. Spoont M. R. Modulatory role of serotonin in neural information processing: implications for human psychopathology. Psychol Bull. 1992 Sep;112(2):330–350. doi: 10.1037/0033-2909.112.2.330. [DOI] [PubMed] [Google Scholar]
  87. Stonehill E., Crisp A. H. Psychoneurotic characteristics of patients with anorexia nervosa before and after treatment and at follow-up 4-7 years later. J Psychosom Res. 1977;21(3):189–193. doi: 10.1016/0022-3999(77)90089-7. [DOI] [PubMed] [Google Scholar]
  88. Strober M. Personality and symptomatological features in young, nonchronic anorexia nervosa patients. J Psychosom Res. 1980;24(6):353–359. doi: 10.1016/0022-3999(80)90027-6. [DOI] [PubMed] [Google Scholar]
  89. Thorén P., Asberg M., Bertilsson L., Mellström B., Sjöqvist F., Träskman L. Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry. 1980 Nov;37(11):1289–1294. doi: 10.1001/archpsyc.1980.01780240087010. [DOI] [PubMed] [Google Scholar]
  90. Virkkunen M., Nuutila A., Goodwin F. K., Linnoila M. Cerebrospinal fluid monoamine metabolite levels in male arsonists. Arch Gen Psychiatry. 1987 Mar;44(3):241–247. doi: 10.1001/archpsyc.1987.01800150053007. [DOI] [PubMed] [Google Scholar]
  91. Virkkunen M., Rawlings R., Tokola R., Poland R. E., Guidotti A., Nemeroff C., Bissette G., Kalogeras K., Karonen S. L., Linnoila M. CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Arch Gen Psychiatry. 1994 Jan;51(1):20–27. doi: 10.1001/archpsyc.1994.03950010020003. [DOI] [PubMed] [Google Scholar]
  92. Vitiello B., Shimon H., Behar D., Stoff D., Bridger W. H., Friedman E. Platelet imipramine binding and serotonin uptake in obsessive-compulsive patients. Acta Psychiatr Scand. 1991 Jul;84(1):29–32. doi: 10.1111/j.1600-0447.1991.tb01417.x. [DOI] [PubMed] [Google Scholar]
  93. Wamsley J. K., Byerley W. F., McCabe R. T., McConnell E. J., Dawson T. M., Grosser B. I. Receptor alterations associated with serotonergic agents: an autoradiographic analysis. J Clin Psychiatry. 1987 Mar;48 (Suppl):19–25. [PubMed] [Google Scholar]
  94. Weizman A., Carmi M., Hermesh H., Shahar A., Apter A., Tyano S., Rehavi M. High-affinity imipramine binding and serotonin uptake in platelets of eight adolescent and ten adult obsessive-compulsive patients. Am J Psychiatry. 1986 Mar;143(3):335–339. doi: 10.1176/ajp.143.3.335. [DOI] [PubMed] [Google Scholar]
  95. Weizman R., Carmi M., Tyano S., Apter A., Rehavi M. High affinity [3H]imipramine binding and serotonin uptake to platelets of adolescent females suffering from anorexia nervosa. Life Sci. 1986 Mar 31;38(13):1235–1242. doi: 10.1016/0024-3205(86)90179-7. [DOI] [PubMed] [Google Scholar]
  96. Welner S. A., De Montigny C., Desroches J., Desjardins P., Suranyi-Cadotte B. E. Autoradiographic quantification of serotonin1A receptors in rat brain following antidepressant drug treatment. Synapse. 1989;4(4):347–352. doi: 10.1002/syn.890040410. [DOI] [PubMed] [Google Scholar]
  97. Zemishlany Z., Modai I., Apter A., Jerushalmy Z., Samuel E., Tyano S. Serotonin (5-HT) uptake by blood platelets in anorexia nervosa. Acta Psychiatr Scand. 1987 Feb;75(2):127–130. doi: 10.1111/j.1600-0447.1987.tb02763.x. [DOI] [PubMed] [Google Scholar]
  98. Zohar J., Insel T. R. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry. 1987 Jun;22(6):667–687. doi: 10.1016/0006-3223(87)90199-5. [DOI] [PubMed] [Google Scholar]
  99. Zohar J., Insel T. R., Zohar-Kadouch R. C., Hill J. L., Murphy D. L. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Arch Gen Psychiatry. 1988 Feb;45(2):167–172. doi: 10.1001/archpsyc.1988.01800260081011. [DOI] [PubMed] [Google Scholar]
  100. Zohar J., Mueller E. A., Insel T. R., Zohar-Kadouch R. C., Murphy D. L. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch Gen Psychiatry. 1987 Nov;44(11):946–951. doi: 10.1001/archpsyc.1987.01800230026006. [DOI] [PubMed] [Google Scholar]
  101. van Praag H. M. CSF 5-HIAA and suicide in non-depressed schizophrenics. Lancet. 1983 Oct 22;2(8356):977–978. doi: 10.1016/s0140-6736(83)90501-9. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Psychiatry and Neuroscience are provided here courtesy of Canadian Medical Association

RESOURCES